NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
Clinical trial NCT07060014 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07060014
- Sponsor
- The Methodist Hospital Research Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-18
- Primary completion
- 2026-09-30
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.